MAPT and frontotemporal dementia: A previous report utilized FTD patient-derived iPSCs that harbor the tau P301L mutation, and generated isogenic lines in which the tau leucine mutation was reverted to proline, as well as targeted knock-in Δp35 in these lines using CRISPR/Cas9 genome-editing [110].